Ribosomally produced
and post-translationally modified
polypeptides
(RiPPs) are a diverse group of natural products that are processed
by a variety of enzymes to their biologically relevant forms. PapB
is a member of the radical S-adenosyl-l-methionine
(rSAM) superfamily that introduces thioether cross-links between Cys
and Asp residues in the PapA RiPP. We report that PapB has high tolerance
for variations in the peptide substrate. Our results demonstrate that
branched side chains in the thiol- and carboxylate-containing residues
are processed and that lengthening of these groups to homocysteine
and homoglutamate does not impair the ability of PapB to form thioether
cross-links. Remarkably, the enzyme can even cross-link a peptide
substrate where the native Asp carboxylate moiety is replaced with
a tetrazole. We show that variations to residues embedded between
the thiol- and carboxylate-containing residues are tolerated by PapB,
as peptides containing both bulky (e.g., Phe) and
charged (e.g., Lys) side chains in both natural L-
and unnatural D-forms are efficiently cross-linked. Diastereomeric
peptides bearing (2S,3R)- and (2S,3S)-methylaspartate are processed by
PapB to form cyclic thioethers with markedly different rates, suggesting
the enzymatic hydrogen atom abstraction event for the native Asp-containing
substrate is diastereospecific. Finally, we synthesized two diastereomeric
peptide substrates bearing E- and Z-configured γ,δ-dehydrohomoglutamate
and show that PapB promotes addition of the deoxyadenosyl radical
(dAdo•) instead of hydrogen atom abstraction. In the Z-configured γ,δ-dehydrohomoglutamate substrate,
a fraction of the dAdo-adduct peptide is thioether cross-linked. In
both cases, there is evidence for product inhibition of PapB, as the
dAdo-adducts likely mimic the native transition state where dAdo•
is poised to abstract a substrate hydrogen atom. Collectively, these
findings provide critical insights into the arrangement of reacting
species in the active site of the PapB, reveal unusual promiscuity,
and highlight the potential of PapB as a tool in the development peptide
therapeutics.